Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 55
Filter
1.
Pharmacogenomics J ; 18(1): 136-143, 2018 01.
Article in English | MEDLINE | ID: mdl-28290528

ABSTRACT

A common haplotype of the flavin-containing monooxygenase gene FMO3 is associated with aberrant mRNA splicing, a twofold reduction in in vivo nicotine N-oxidation and reduced nicotine dependence. Tobacco remains the largest cause of preventable mortality worldwide. CYP2A6, the primary hepatic nicotine metabolism gene, is robustly associated with cigarette consumption but other enzymes contribute to nicotine metabolism. We determined the effects of common variants in FMO3 on plasma levels of nicotine-N-oxide in 170 European Americans administered deuterated nicotine. The polymorphism rs2266780 (E308G) was associated with N-oxidation of both orally administered and ad libitum smoked nicotine (P⩽3.3 × 10-5 controlling for CYP2A6 genotype). In vitro, the FMO3 G308 variant was not associated with reduced activity, but rs2266780 was strongly associated with aberrant FMO3 mRNA splicing in both liver and brain (P⩽6.5 × 10-9). Surprisingly, in treatment-seeking European American smokers (n=1558) this allele was associated with reduced nicotine dependence, specifically with a longer time to first cigarette (P=9.0 × 10-4), but not with reduced cigarette consumption. As N-oxidation accounts for only a small percentage of hepatic nicotine metabolism we hypothesized that FMO3 genotype affects nicotine metabolism in the brain (unlike CYP2A6, FMO3 is expressed in human brain) or that nicotine-N-oxide itself has pharmacological activity. We demonstrate for the first time nicotine N-oxidation in human brain, mediated by FMO3 and FMO1, and show that nicotine-N-oxide modulates human α4ß2 nicotinic receptor activity in vitro. These results indicate possible mechanisms for associations between FMO3 genotype and smoking behaviors, and suggest nicotine N-oxidation as a novel target to enhance smoking cessation.


Subject(s)
Brain/metabolism , Nicotine/adverse effects , Nicotine/metabolism , Oxygenases/genetics , Oxygenases/metabolism , Polymorphism, Genetic/genetics , Tobacco Use Disorder/genetics , Alleles , Animals , Cells, Cultured , Genotype , Haplotypes/genetics , Humans , Male , Middle Aged , Oocytes/metabolism , Oxidation-Reduction , Smoking/genetics , Smoking/metabolism , Tobacco Use Disorder/metabolism , White People , Xenopus/genetics
2.
J Basic Clin Physiol Pharmacol ; 20(3): 233-63, 2009.
Article in English | MEDLINE | ID: mdl-19852310

ABSTRACT

The goal of the present study was to apply the oscillatory brain dynamics model to the structural and quantitative analysis of neurocognitive functions considered as a potential marker of schizophrenia. This was achieved in tests of the detection of auditory events deviating in the regular auditory stream (oddball paradigm, MMN effect). It was hypothesized that the post-stimulus peaks of the oscillation power localized in post-stimulus time in the definite EEG oscillators represented neuro-electrical 'events' evoked in the specific neuronal nets characterized by this oscillation frequency band. We suggest that the time-frequency destination of these events related to the activation of the functional neuronal nets could be used for the determination of specific neurocognitive functions. Thus it was an attempt to distinguish the different neuro-functional parts of auditory processing and to compare these results between healthy subjects and patients with schizophrenia. The present results demonstrate the significant difference between the frontal averaged EEG oscillatory dynamics in healthy subjects and patients with schizophrenia related to neurocognitive function marked by the MMN and orienting response N200/P300a.


Subject(s)
Cognition Disorders/physiopathology , Electroencephalography , Evoked Potentials, Auditory , Schizophrenia/physiopathology , Acoustic Stimulation/methods , Adult , Analysis of Variance , Case-Control Studies , Cognition Disorders/etiology , Frontal Lobe/physiopathology , Humans , Male , Nerve Net/metabolism , Young Adult
3.
Schizophr Res ; 111(1-3): 23-31, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19361958

ABSTRACT

Some forms of epigenetic abnormalities transmitted to offspring are manifested in differences in disease incidence that depend on parent-of-origin. To explore whether such phenomena might operate in schizophrenia spectrum disorders, we estimated the relative incidence of these conditions in relation to parent-of-origin by considering the two grandfathers' countries of birth. In a prospective cohort of 88,829 offspring, born in Jerusalem in 1964-76 we identified 637 cases through Israel's psychiatric registry. Relative risks (RR) were estimated for paternal and maternal grandfathers' countries of birth using proportional hazards methods, controlling for parents' ages, low social class and duration of marriage. After adjusting for multiple observations, we found no significant differences between descendants of maternal or paternal grandfathers born in Iraq, Iran, Turkey, Syria, Yemen, Morocco, Algeria, Tunisia, Libya/Egypt, Poland, USSR, Czechoslovakia, Germany or the USA. Those with paternal grandfathers from Romania (RR=1.9, 95% CI=1.3-2.8) or Hungary (1.6, 1.0-2.6) showed an increased incidence; however, those with maternal grandfathers from these countries experienced reduced incidence (RR=0.5, 0.3-0.8 and 0.4, 0.2-0.8). In post-hoc analyses we found that results were similar whether the comparison groups were restricted to descendants of other Europeans or included those from Western Asia and North Africa; and effects of paternal grandfathers from Romania/Hungary were more pronounced in females, while effects of maternal grandfathers from these countries were similar in males and females. These post-hoc "hypothesis-generating" findings lead one to question whether some families with ancestors in Romania or Hungary might carry a variant or mutation at a parentally imprinted locus that is altering susceptibility to schizophrenia. Such a locus, if it exists, might involve the X chromosome.


Subject(s)
Family Health , Parents , Population Dynamics , Risk , Schizophrenia/epidemiology , Schizophrenia/genetics , Age Factors , Cohort Studies , Consanguinity , Female , Humans , Incidence , Internationality , Israel/epidemiology , Male , Retrospective Studies , Socioeconomic Factors
4.
CNS Drugs ; 15(3): 185-95, 2001.
Article in English | MEDLINE | ID: mdl-11463127

ABSTRACT

Kleptomania--the inability to resist the impulse to steal objects, not for personal use or monetary gain--is currently classified in psychiatric nomenclature as an impulse control disorder. However, some of the principle features of the disorder, which include repetitive intrusion thoughts, inability to resist the compulsion to perform the thievery and the relief of tension following the act, suggest that kleptomania may constitute an obsessive-compulsive spectrum disorder. Kleptomania is commonly under-diagnosed and is often accompanied by other psychiatric conditions, most notably affective, anxiety and eating disorders, and alcohol and substance abuse. Individuals with the disorder are usually referred for treatment due to the comorbid psychiatric complaints rather than kleptomanic behaviour per se. Over the past century there has been a shift from psychotherapeutic to psychopharmacological interventions for kleptomania. Pharmacological management using selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) and other antidepressants, mood stabilisers and opioid receptor antagonists, as adjuvants to cognitive-behavioural therapy, has produced promising results.


Subject(s)
Antidepressive Agents/therapeutic use , Disruptive, Impulse Control, and Conduct Disorders/diagnosis , Disruptive, Impulse Control, and Conduct Disorders/therapy , Narcotic Antagonists/therapeutic use , Selective Serotonin Reuptake Inhibitors/therapeutic use , Disruptive, Impulse Control, and Conduct Disorders/psychology , Humans , Psychotherapy/methods
6.
Bone Marrow Transplant ; 26(7): 729-35, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11042653

ABSTRACT

Between April 1997 and March 1998 we evaluated the immune response and outcome in 11 chemosensitive patients who were treated with the anti-idiotype antibody vaccine TriAb after recovery from intensive therapy and autologous stem cell transplant (ASCT). Triab was commenced after recovery from the acute effects of ASCT; a minimum interval of 1 month was required from completion of consolidation radiotherapy, if given. Nine patients (82%) manifest anti-anti-idiotype antibody (Ab3) responses post ASCT. The maximal Ab3 response was seen after a median of 10 doses (range 5-20), which corresponded to a median of 14 months (range 5-19) post ASCT. Evidence of a T cell proliferative response was seen in eight patients; the response was modest in most of these. At a median follow-up of 24 months (range 22-33) after ASCT, four patients are alive without evidence of disease progression. All four of these patients were in the subgroup with more vigorous immune responses. Subsequent efforts have been directed toward the achievement of higher levels of immune responses more rapidly post ASCT. Bone Marrow Transplantation (2000) 26, 729-735.


Subject(s)
Antibodies, Anti-Idiotypic/therapeutic use , Breast Neoplasms/therapy , Cancer Vaccines/therapeutic use , Hematopoietic Stem Cell Transplantation , Adult , Aged , Antibodies, Anti-Idiotypic/toxicity , Antigens, Neoplasm/immunology , Antineoplastic Combined Chemotherapy Protocols/immunology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/immunology , Bone Neoplasms/secondary , Bone Neoplasms/therapy , Breast Neoplasms/immunology , Breast Neoplasms/pathology , Cancer Vaccines/immunology , Cancer Vaccines/toxicity , Disease-Free Survival , Female , Follow-Up Studies , Humans , Immunotherapy , Liver Neoplasms/immunology , Liver Neoplasms/secondary , Liver Neoplasms/therapy , Lymphatic Metastasis/immunology , Lymphocyte Activation , Middle Aged , Time Factors , Transplantation, Autologous , Treatment Outcome
8.
Mil Med ; 165(6): 480-2, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10870368

ABSTRACT

Psychiatrists from the former Soviet Union serve in the Department of Mental Health of the Israel Defense Forces. The new immigrant psychiatrists confront a wide range of difficulties during the process of integration to the military system and adaptation to the specifically military aspects of psychiatry. These include unfamiliarity with the military system, cultural clashes with the different groups of soldiers representing the various subgroups of the absorbing society, the psychopathology of soldiers, which is different from that seen in civil psychiatry, and the change in focus in the military mental health service, which emphasizes the importance of evaluating ego strength. Arbitrarily, one can describe four stages of adaptation that the immigrant psychiatrist has to pass through before recruitment and during service until adaptation and integration in the new role take place. Individual and group supervision are the main means by which the assimilation process is eased. The military service smooth the acculturation process and has an important role in helping the immigrant's adaptation to Israeli society and in building his or her professional identity.


Subject(s)
Acculturation , Emigration and Immigration , Military Personnel/psychology , Military Psychiatry , Adaptation, Psychological , Humans , Israel , Models, Psychological , Social Identification , USSR/ethnology
9.
J Clin Oncol ; 18(2): 376-84, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10637253

ABSTRACT

PURPOSE: To determine immune responses and toxicity to the anti-idiotype vaccine, as well as clinical responses and survival, we initiated a clinical trial for patients with advanced melanoma treated with an anti-idiotype antibody (TriGem) that mimics the disialoganglioside GD2. PATIENTS AND METHODS: Forty-seven patients with advanced melanoma received either 1-, 2-, 4-, or 8-mg doses of TriGem (Titan Pharmaceuticals Inc, South San Francisco, CA) mixed with QS-21 adjuvant (Aquila Biopharmaceuticals, Inc, Worcester, MA) 100 microg subcutaneously weekly for 4 weeks and then monthly until disease progression. Median age was 57 years, there were 32 men and 15 women, 43% of patients had undergone prior therapy for metastatic disease, 55% had disease confined to soft tissue, and 45% had visceral metastasis. RESULTS: Hyperimmune sera from 40 of 47 patients showed an anti-anti-idiotype (Ab3) response. Patient Ab3 was truly Ab1' because it specifically bound purified disialoganglioside GD2. The isotypic specificity of the Ab3 antibody consisted of predominantly immunoglobulin (Ig)G, and all IgG subclasses were represented. One patient had a complete response that persisted at 24 months, and 12 patients were stable from 14+ to 37+ months (median, 18+ months). Disease progression occurred in 32 patients on study from 1 to 17 months (median, 5.5 months), and 21 have died at 1 to 16 months (median, 6 months). The Kaplan-Meier-derived overall median survival has not been reached. Median survival has not been reached for the 26 patients with soft tissue disease only and was 13 months for 21 patients with visceral metastasis. Toxicity consisted of local reaction at the site of injection and mild fever and chills. CONCLUSION: TriGem has minimal toxicity and generates robust and specific IgG immune responses against GD2. Objective responses were minimal, but there may be a favorable impact on disease progression and survival that will require prospective randomized trials.


Subject(s)
Antibodies, Anti-Idiotypic/immunology , Gangliosides/immunology , Immunoglobulin G/immunology , Melanoma/immunology , Skin Neoplasms/immunology , Adolescent , Adult , Aged , Aged, 80 and over , Antibodies, Anti-Idiotypic/therapeutic use , Antibody Specificity , Disease Progression , Female , Gangliosides/therapeutic use , Humans , Immunization , Male , Melanoma/pathology , Melanoma/therapy , Middle Aged , Skin Neoplasms/pathology , Skin Neoplasms/therapy , Survival Analysis
10.
J Clin Oncol ; 17(9): 2889-5, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10561367

ABSTRACT

PURPOSE: We generated an anti-idiotype antibody, designated CeaVac, that is an internal image of the carcinoembryonic antigen (CEA). We previously demonstrated that the majority of patients with advanced colorectal cancer generate specific anti-CEA responses. The purpose of the current study was to treat patients with surgically resected colon cancer with CeaVac to determine the immune response and clinical outcome to treatment with vaccine. We also compared the immune responses between patients treated with fluorouracil (5-FU) chemotherapy regimens plus vaccine versus vaccine alone. PATIENTS AND METHODS: Thirty-two patients with resected Dukes' B, C, and D, and incompletely resected Dukes' D disease were treated with 2 mg of CeaVac every other week for four injections and then monthly until tumor recurrence or progression. Fourteen patients were treated concurrently with 5-FU chemotherapy regimens. RESULTS: All 32 patients entered onto this trial generated high-titer immunoglobulin G and T-cell proliferative immune responses against CEA. The 5-FU regimens did not have a qualitative or quantitative effect on the immune response. Three of 15 patients with Dukes' B and C disease progressed at 19, 24, and 35 months. Seven of eight patients with completely resected Dukes' D disease remained on study from 12 to 33 months; one patient with resected Dukes' D disease relapsed at 9 months. One patient with incompletely resected Dukes' D disease remained on study at 14 months without evidence of progression; eight experienced disease progression at 6 to 31 months. CONCLUSION: CeaVac consistently generated a potent anti-CEA humoral and cellular immune response in all 32 patients entered onto this trial. A number of very high-risk patients continue on study. 5-FU regimens, which are the standard of care for patients with Dukes' C disease, did not affect the immune response. These data warrant a phase III trial for patients with resected colon cancer.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Cancer Vaccines/therapeutic use , Carcinoembryonic Antigen/immunology , Carcinoembryonic Antigen/therapeutic use , Colonic Neoplasms/therapy , Adjuvants, Immunologic/therapeutic use , Aluminum Hydroxide/therapeutic use , Animals , Antibodies, Anti-Idiotypic/immunology , Antimetabolites, Antineoplastic/therapeutic use , CD4-Positive T-Lymphocytes/immunology , Colonic Neoplasms/immunology , Colonic Neoplasms/pathology , Fluorouracil/therapeutic use , Humans , Immunity, Cellular , Immunoglobulin G/immunology , Mice , Mice, Inbred BALB C , Neoplasm Staging , Saponins/therapeutic use
11.
Isr J Psychiatry Relat Sci ; 36(2): 122-8, 1999.
Article in English | MEDLINE | ID: mdl-10472746

ABSTRACT

Clozapine is an "atypical" antipsychotic agent for treating previously resistant schizophrenic patients. Its main advantages over "typical" neuroleptics are low incidence of extrapyramidal side effects and its capacity to induce therapeutic response in previously treated refractory patients. However, withdrawal from clozapine has been observed to lead to "atypical" clinical characteristics or a "rebound phenomenon," manifested in two interwoven clinical forms: (1) psychotic exacerbation, and (2) cholinergic rebound. The underlying pathophysiological mechanism of this phenomenon is postulated to be a result of cholinergic supersensitivity. In this paper, the "rebound phenomenon" will be discussed and exemplified by three case histories in which abrupt cessation of clozapine led to serious deterioration and psychotic exacerbation, and one case in which gradual titration from the drug was employed in order to preempt this hazardous occurrence.


Subject(s)
Antipsychotic Agents/therapeutic use , Clozapine/adverse effects , Schizophrenia/drug therapy , Substance Withdrawal Syndrome/diagnosis , Adult , Chronic Disease , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Substance Withdrawal Syndrome/psychology
12.
Isr J Psychiatry Relat Sci ; 36(1): 47-54, 1999.
Article in English | MEDLINE | ID: mdl-10389363

ABSTRACT

Differentiation between psychogenic and organic amnesia is sometimes quite difficult. This paper focuses on the psychogenic and organic components of a complex case of amnesia rooted in remote and prolonged traumatic stress and manifested under circumstances evoking dissociated memories. The Transient Global Amnesia (TGA) of a concentration camp survivor who developed sudden amnesia during a psychiatric intake interview was clearly triggered by the pressure of repressed Holocaust memories. The importance of distinguishing between TGA and dissociative amnesia is emphasized, and the role of psychological upset as a precipitant in TGA is stressed.


Subject(s)
Amnesia/psychology , Holocaust/psychology , Life Change Events , Repression, Psychology , Survivors/psychology , Acute Disease , Affect/physiology , Aged , Amnesia/diagnosis , Amnesia/therapy , Female , Humans
13.
Psychiatr Serv ; 50(5): 698-700, 1999 May.
Article in English | MEDLINE | ID: mdl-10332910

ABSTRACT

The effectiveness of Israel's compulsory ambulatory treatment order was evaluated based on a one-year follow-up of the 326 orders served during the first four years of implementation. Demographic, epidemiological, clinical, and legal data were obtained from patient records. Success was defined as continuous treatment for the entire six-month period of compulsory ambulatory treatment, or as voluntary hospitalization during or after the compulsory treatment period. The compulsory ambulatory treatment order was found to be efficacious in 43.3 percent of the cases; in 32.5 percent it did not succeed in preventing compulsory hospitalization, and in the remaining cases (22.1 percent), success was partial.


Subject(s)
Ambulatory Care/legislation & jurisprudence , Commitment of Mentally Ill/legislation & jurisprudence , Mental Disorders/therapy , Adult , Ambulatory Care/standards , Chi-Square Distribution , Commitment of Mentally Ill/standards , Diagnosis-Related Groups/statistics & numerical data , Female , Hospitalization/statistics & numerical data , Humans , Israel , Male , Patient Compliance , Retrospective Studies , Treatment Outcome
15.
J Diabetes Complications ; 11(4): 236-42, 1997.
Article in English | MEDLINE | ID: mdl-9201601

ABSTRACT

In liver cells from diabetic rats, an increased incorporation of labeled glucosamine into cellular and secretory proteins was found, when related to the incorporation of labeled leucine. This increased N-glycosylation was present in the face of decreased synthesis of hepatic cellular and secretory proteins evident from reduced leucine incorporation and diminished glycosyltransferase activity. To elucidate the mechanisms involved we incubated isolated hepatocytes with two N-glycosylation inhibitors: tunicamycin and 2-deoxyglucose. Tunicamycin exerted a marked inhibitory effect on the incorporation rate of labeled glucosamine into proteins in liver cells from diabetic rats, while 2-deoxyglucose had a negligible effect on this process in these cells. These diverse effects might be explained by the fact that tunicamycin acts through strong association with the enzyme catalyzing the first step in glycoprotein synthesis, namely, the transfer of UDP-GlcNAc to dolichol-P (indicating noncompetitive inhibition). This enzyme is reduced in liver cells from diabetic animals. On the other hand, 2-deoxyglucose exerts its effect by being attached to dolichol-P, preventing further elongation of oligosaccharide chain on the protein backbone. This latter effect might be eliminated by excess dolichol-P (indicating competitive inhibition). The dolichol content in liver extract from diabetic rats was about 2.5-fold higher compared with nondiabetic rats (51.6 micrograms/g versus 20.6 micrograms/g wet liver weight). These two lines of evidence confirm the notion that the enhanced enzymatic glycosylation in liver from diabetic animals is maintained by an increased hepatic dolichol concentration, which is most probably related to the hyperglycemia. Thus, the dolichol-N-glycosylation pathway may represent another detrimental aspect of hyperglycemia and may operate by dolichol mass action rather than through glycosylating enzyme activity.


Subject(s)
Diabetes Mellitus, Experimental/metabolism , Dolichols/metabolism , Hyperglycemia/metabolism , Liver/metabolism , Proteins/metabolism , Animals , Deoxyglucose/pharmacology , Glucosamine/metabolism , Glycosylation , Leucine/metabolism , Liver/drug effects , Male , Rats , Tunicamycin/pharmacology
16.
Harefuah ; 133(12): 597-602, 664, 1997 Dec 15.
Article in Hebrew | MEDLINE | ID: mdl-9451866

ABSTRACT

The Treatment of Mentally Sick Persons Law of 1955, was repealed and replaced by the Law of 1991. Under the latter, the Order for Compulsory Ambulatory Treatment (OCAT) was addressed for the first time (Section 11, a-d). According to this law, the district psychiatrist instead of issuing a hospitalization order, may issue an OCAT, under which the required treatment is given within the scope of a clinic which he designates, for up to 6 months and under conditions which he specifies. This is done on the basis of psychiatric examination, or an application in writing from the director of a hospital or clinic, when continued ambulatory treatment is needed after discharge from hospital or instead of compulsory hospitalization. The district psychiatrist may extend the period of treatment for further periods, none of which is to exceed 6 months. Compulsory ambulatory treatment is to enable patients to benefit from the positive aspects of living freely in the community, while receiving prompt treatment under compulsory conditions. The concept offers a partial solution, achieving a balance between civil liberties and clinical needs, between over-confinement and under-treatment which might be dangerous or neglectful. The clinical impression has been that the OCAT has not fulfilled expectations. The purpose of this study was to examine the topic in a systematic way in Jerusalem and the southern districts for the 4 years since inception of the law. In 44.4% of cases OCAT was proven to be effective, while in 33.1% it was found to be ineffective and did not prevent compulsory hospitalization, one of its main goals. It was partially effective in the rest of the cases. It is recommended that suitable means for the enforcement of the law be allocated and that the subject of forceful hospitalization and OCAT be made a mandatory subject in the residency program of psychiatrists.


Subject(s)
Ambulatory Care/legislation & jurisprudence , Legislation, Medical , Mental Disorders/therapy , Psychiatry/legislation & jurisprudence , Civil Rights/legislation & jurisprudence , Delivery of Health Care/legislation & jurisprudence , Humans , Israel
17.
J Urol ; 153(2): 427-8, 1995 Feb.
Article in English | MEDLINE | ID: mdl-7815608

ABSTRACT

The koro syndrome is a psychiatric disorder characterized by acute anxiety and a deep-seated fear of shrinkage of the penis and its ultimate retraction into the abdomen, which will cause death. Concurrence of the koro (genital retraction) syndrome with a pathological condition of the urogenital system has rarely been described. We report a case of koro associated with infertility. Within 3 weeks of treatment with haloperidol the classic symptoms of koro disappeared. To our knowledge this case represents the sixth report of the koro syndrome associated with urogenital pathology and the first report of its association with infertility.


Subject(s)
Infertility, Male/complications , Jews , Koro/complications , Adult , Humans , Male
19.
Harefuah ; 124(11): 673-6, 740, 1993 Jun 01.
Article in Hebrew | MEDLINE | ID: mdl-8344622

ABSTRACT

Koro syndrome is a triad which includes a deep-seated fear that the penis will shrink, disappear into the abdomen, and that death will follow. The patient experiences profound anxiety and performs preventive manoeuvres, such as pulling his penis outward. The disorder is considered culture-related, and is endemic in South-East Asia and China, where it occurs in epidemic and sporadic forms. Sporadic cases appear in the western hemisphere, often in association with an underlying psychiatric or organic disorder, usually of the central nervous system. 6 cases of koro have been published from Israel.


Subject(s)
Koro , Adult , Culture , Humans , Israel , Koro/psychology , Male
20.
J Interferon Res ; 10(6): 559-70, 1990 Dec.
Article in English | MEDLINE | ID: mdl-2086672

ABSTRACT

To assess biological response, therapeutic activity, and side effects, a randomized, double-blind trial of two doses of interferon-beta ser (IFN-beta ser), differing by 20-fold 4.5 and 90 x 10(6) units), was undertaken in 64 patients with metastatic renal carcinoma. Patients were treated intravenously with injections daily for 10 days with an 11-day rest before treatment was reinitiated. The trial confirmed the relatively good toleration of IFN-beta ser; in the first cycle only 4/63 patients had anorexia of moderate or greater severity. Median weight change over the duration on study was -1.5 kg; in the first cycle only 7% of patients had performance status decline greater than 1 level. Statistically significant changes (p less than 0.05) occurred in granulocytes, lymphocytes, calcium, cholesterol, alkaline phosphatase, and aspartate transferase (AST); however, except for AST, overall clinical differences in the two doses were not great. Of 60 patients evaluated, 1 developed neutralizing antibody. When assessed 24 h after IFN-beta ser at 4.5 x 10(6) units, significant (p less than 0.05) augmentation had occurred in beta 2-microglobulin, HLA-DR, and HLA-DQ expression on monocytes, 2',5'-oligoadenylate (2-5A) synthetase in peripheral mononuclear cells, and natural killer (NK) and K cells functional activity. Although the 90 x 10(6) unit dose also resulted in stimulation of these responses, little additional augmentation of biological response occurred at the higher dose. Except for a decline in monocyte HLA-DR expression, biological responses remained increased at both doses over the 10-day period of treatment. However, no objective regressions of metastatic disease occurred. In view of objective responses in metastatic renal carcinoma in other trials with IFN-beta ser, consideration should be given to alternative schedules.


Subject(s)
Interferon Type I/administration & dosage , Interferon-beta , Kidney Neoplasms/therapy , Recombinant Proteins/administration & dosage , 2',5'-Oligoadenylate Synthetase/blood , Adult , Dose-Response Relationship, Immunologic , Double-Blind Method , HLA Antigens , Humans , Immunotherapy , Interferon beta-1a , Interferon beta-1b , Kidney Neoplasms/physiopathology , Kidney Neoplasms/secondary
SELECTION OF CITATIONS
SEARCH DETAIL
...